thalidomide

P=N/A, N=240, Not yet recruiting, Riphah International University

P2, N=60, Recruiting, Sarcoma Oncology Research Center, LLC

P4, N=90, Completed, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting --> Completed | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Jun 2024 --> Jan 2026

Clinically validated examples include thalidomide analogs that recruit cereblon (CRBN) to degrade IKAROS family zinc finger 1/3 in multiple myeloma, and arylsulfonamide-based MGDs that promote the degradation of RNA-binding protein 39 in acute myeloid leukemia and solid tumors...By integrating multidisciplinary discovery strategies with translational oncology, the field is moving toward the development of next-generation MGDs with enhanced specificity, broader substrate scope, and improved resistance profiles. This study aims to elucidate how these innovations expand the degradable proteome and establish MGDs as a cornerstone of precision cancer therapy, thereby redefining the boundaries of drug discovery and providing customizable degraders tailored to diverse cancer contexts.

P2, N=45, Recruiting, Medicines Development for Global Health | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> May 2026

P3, N=382, Active, not recruiting, University of Arkansas | Trial completion date: Sep 2027 --> Sep 2028 | Trial primary completion date: Sep 2026 --> Sep 2027

P2, N=90, Active, not recruiting, University of Arkansas | Trial primary completion date: Oct 2026 --> Oct 2027 | Trial completion date: Oct 2027 --> Oct 2028

P2, N=160, Active, not recruiting, University of Arkansas | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

P3, N=306, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027

P4, N=50, Completed, Suzhou Municipal Hospital; Suzhou Municipal Hospital

P=N/A, N=50, Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College

In our real-life study, we confirmed the strong negative impact of lenalidomide on PBSC collection by comparing lenalidomide-treated patients with a control cohort of thalidomide-treated subject, also showing a more frequent use of plerixafor to mitigate these effects, thereby reducing the reliance on cyclophosphamide, that was associated with lower risk of prolonged apheresis sessions. Indeed, we showed that lenalidomide use significantly impaired stem cell collection, with prolonged apheresis sessions and lower CD34+ cell collection on day 1, while post-transplant outcomes did not significantly differ between groups. Our real-life bi-center experience is of great interest in the era of daratumumab-based regimens as first-line therapy for autologous stem cell transplantation-eligible MM patients, because the concomitant use with lenalidomide might negatively affect PBSC mobilization, urging for more tailored PBSC collection strategies.